Methods for Treating or Preventing Ophthalmological Conditions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 16/434,018, filed Jun 6, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,273,171 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence | ||
| US 11,491,176 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence | ||
| US 12,016,875 | Methods for Treating or Preventing Ophthalmological Conditions In force · High confidence | Astellas US LLC | In force | High confidence | ||
| Application 17/958,710 | Methods for Treating or Preventing Ophthalmological Conditions Abandoned Abandoned Jun 24, 2025 | Astellas US LLC | Abandoned | Abandoned Jun 24, 2025 | ||
| Application 18/132,253 | Methods for Treating or Preventing Ophthalmological Conditions Abandoned Abandoned Aug 25, 2025 | Astellas US LLC | Abandoned | Abandoned Aug 25, 2025 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Astellas US LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.